Showing 441 - 460 results of 2,381 for search '"labelling"', query time: 0.10s Refine Results
  1. 441
  2. 442
  3. 443

    Anti-LAG-3 antibody LBL-007 plus anti-PD-1 antibody toripalimab in advanced nasopharyngeal carcinoma and other solid tumors: an open-label, multicenter, phase Ib/II trial by Gang Chen, Dong-Chen Sun, Yi Ba, Ya-Xiong Zhang, Ting Zhou, Yuan-Yuan Zhao, Hong-Yun Zhao, Wen-Feng Fang, Yan Huang, Zhen Wang, Chao Deng, De-Sheng Hu, Wei Wang, Jin-Guan Lin, Gui-Ling Li, Su-Xia Luo, Zhi-Chao Fu, Hai-Sheng Zhu, Hui-Li Wang, Sheng-Li Cai, Xiao-Qiang Kang, Li Zhang, Yun-Peng Yang

    Published 2025-02-01
    “…Abstract Purpose Open-label phase Ib/II study to investigate the safety and efficacy of LBL-007, an anti-LAG-3 antibody, plus toripalimab, an anti-PD-1 antibody, in patients with previously treated advanced nasopharyngeal carcinoma (NPC) and other solid tumors. …”
    Get full text
    Article
  4. 444
  5. 445

    AOZORA: long-term safety and joint health in paediatric persons with haemophilia A without factor VIII inhibitors receiving emicizumab – protocol for a multicentre, open-label, phase IV clinical study by Seitaro Yoshida, Masashi Taki, Hideyuki Takedani, Midori Shima, Keiji Nogami, Azusa Nagao, Haruko Yamaguchi-Suita, Yui Kyogoku, Akira Ishiguro, Kaoru Kitsukawa

    Published 2022-06-01
    “…The AOZORA study will evaluate the long-term safety and joint health of paediatric PwHA without factor (F)VIII inhibitors taking emicizumab; here, we report the details of the study protocol and baseline data.Methods and analysis AOZORA is a multicentre, open-label, phase IV clinical study in Japan that aims to enrol approximately 30 PwHA aged <12 years without FVIII inhibitors. …”
    Get full text
    Article
  6. 446
  7. 447
  8. 448
  9. 449
  10. 450
  11. 451
  12. 452
  13. 453
  14. 454
  15. 455

    Prevention of Acute Radiation-Induced Skin Reaction with NPE® Camellia Sinensis Nonfermentatum Extract in Female Breast Cancer Patients Undergoing Postoperative Radiotherapy: A Single Centre, Prospective, Open-Label Pilot Study by Gabriela Näf, Urs E. Gasser, Hans E. Holzgang, Sandra Schafroth, Christoph Oehler, Daniel R. Zwahlen

    Published 2018-01-01
    “…Twenty patients were enrolled in this single centre, prospective, open-label pilot study. The outcomes of 20 prospective data sets were compared with 100 retrospectively collected matched data sets derived from hospital records. …”
    Get full text
    Article
  16. 456

    Combined use of respiratory multiplex PCR and procalcitonin to reduce antibiotic exposure in sickle-cell adult patients with acute chest syndrome (The ANTIBIO-STA study): a randomised, controlled, open-label trialResearch in context by Alexandre Sabaté-Elabbadi, Armand Mekontso-Dessap, François Lionnet, Aline Santin, Charlotte Verdet, Paul-Louis Woerther, Julien Lopinto, Matthieu Turpin, Alexandra Rousseau, Romane Lacoste-Badie, Keyvan Razazi, Guillaume Voiriot, Muriel Fartoukh

    Published 2025-04-01
    “…Methods: We conducted a randomised, controlled, parallel group, open-label study in two French hospitals. Consecutive adult patients with ACS were randomly assigned to the conventional or interventional strategy, where antibiotic therapy was targeted on the results of mPCR performed on lower respiratory tract secretions (LRTS) samples, and antibiotic discontinuation based on PCT values and kinetics at Day 1 (D1), D3 and D7. …”
    Get full text
    Article
  17. 457
  18. 458
  19. 459

    Efficacy and safety of NeoAdjuvant chemotherapy with or without tIslelizumab followed by debulking surgery for oVarian cancEr (NAIVE study) in China: study protocol of an open-label, phase II, randomised controlled trial by Ying Zhu, Jianwei Zhou, Zhigang Zhang, Jiaojiao Zhang, Jing Fei, Xiaoqing Zhu

    Published 2025-02-01
    “…The NeoAdjuvant chemotherapy with or without tIslelizumab followed by debulking surgery for oVarian cancEr(NAIVE) study aims to assess the clinical efficacy and safety of NACT in combination with tislelizumab (a monoclonal antibody for programmed cell death protein 1) for advanced EOC.Methods and analysis The NAIVE study is an investigator-initiated, prospective, single-centre, open-label, randomised controlled trial for advanced EOC with the International Federation of Gynaecology and Obstetrics (FIGO) stage IIIc with a Suidan CT score of 3 or greater or a Fagotti laparoscopic score of 8 or greater; or FIGO stage IV. …”
    Get full text
    Article
  20. 460